Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ENOV NASDAQ:IRMD NASDAQ:SLNO NASDAQ:TMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENOVEnovis$32.41+3.1%$30.96$25.47▼$49.83$1.80B1.69621,844 shs624,496 shsIRMDiRadimed$74.69+1.7%$71.92$46.86▼$78.38$933.67M1.0255,057 shs34,092 shsSLNOSoleno Therapeutics$65.450.0%$64.77$41.50▼$90.32$3.48B-2.751.74 million shs2.06 million shsTMDXTransMedics Group$119.90+1.9%$116.37$55.00▼$145.50$4.01B2.08817,567 shs986,312 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENOVEnovis+3.18%+8.90%+0.12%+18.90%-21.45%IRMDiRadimed+1.72%+3.15%+5.91%+32.66%+44.16%SLNOSoleno Therapeutics-0.03%+1.84%+19.57%-23.91%+20.85%TMDXTransMedics Group+1.93%+7.33%-1.95%+13.54%-5.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENOVEnovis$32.41+3.1%$30.96$25.47▼$49.83$1.80B1.69621,844 shs624,496 shsIRMDiRadimed$74.69+1.7%$71.92$46.86▼$78.38$933.67M1.0255,057 shs34,092 shsSLNOSoleno Therapeutics$65.450.0%$64.77$41.50▼$90.32$3.48B-2.751.74 million shs2.06 million shsTMDXTransMedics Group$119.90+1.9%$116.37$55.00▼$145.50$4.01B2.08817,567 shs986,312 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENOVEnovis+3.18%+8.90%+0.12%+18.90%-21.45%IRMDiRadimed+1.72%+3.15%+5.91%+32.66%+44.16%SLNOSoleno Therapeutics-0.03%+1.84%+19.57%-23.91%+20.85%TMDXTransMedics Group+1.93%+7.33%-1.95%+13.54%-5.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENOVEnovis 2.71Moderate Buy$51.0057.36% UpsideIRMDiRadimed 3.00Buy$72.00-3.60% DownsideSLNOSoleno Therapeutics 2.93Moderate Buy$115.9277.11% UpsideTMDXTransMedics Group 2.54Moderate Buy$127.186.07% UpsideCurrent Analyst Ratings BreakdownLatest IRMD, TMDX, SLNO, and ENOV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025TMDXTransMedics GroupCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$142.0010/13/2025TMDXTransMedics GroupJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$145.0010/8/2025ENOVEnovisWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025IRMDiRadimedWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B-)10/8/2025SLNOSoleno TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TMDXTransMedics GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/7/2025SLNOSoleno TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$125.0010/7/2025SLNOSoleno TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$125.0010/6/2025TMDXTransMedics GroupZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/29/2025TMDXTransMedics GroupZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/27/2025ENOVEnovisWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENOVEnovis$2.11B0.88$19.88 per share1.63$45.10 per share0.72IRMDiRadimed$73.24M12.97$1.61 per share46.41$6.85 per share10.90SLNOSoleno TherapeuticsN/AN/AN/AN/A$5.68 per shareN/ATMDXTransMedics Group$441.54M9.26$1.68 per share71.49$6.81 per share17.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENOVEnovis-$825.49M-$14.25N/A10.16N/A-37.80%6.78%3.73%11/5/2025 (Estimated)IRMDiRadimed$19.23M$1.6246.1037.35N/A26.61%23.30%20.62%10/30/2025 (Estimated)SLNOSoleno Therapeutics-$175.85M-$4.14N/AN/AN/AN/A-73.74%-56.67%11/5/2025 (Estimated)TMDXTransMedics Group$35.46M$1.9362.1283.85N/A13.49%28.02%8.64%10/29/2025 (Estimated)Latest IRMD, TMDX, SLNO, and ENOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025ENOVEnovis$0.67N/AN/AN/A$538.61 millionN/A11/5/2025Q3 2025SLNOSoleno Therapeutics$0.08N/AN/AN/A$47.46 millionN/A10/30/2025Q3 2025IRMDiRadimed$0.43N/AN/AN/A$20.50 millionN/A10/29/2025Q3 2025TMDXTransMedics Group$0.37N/AN/AN/A$145.33 millionN/A8/7/2025Q2 2025ENOVEnovis$0.74$0.79+$0.05-$0.64$555.80 million$564.50 million8/6/2025Q2 2025SLNOSoleno Therapeutics-$0.53-$0.09+$0.44-$0.09$3.91 million$32.66 million7/30/2025Q2 2025TMDXTransMedics Group$0.48$0.92+$0.44$0.92$146.64 million$157.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENOVEnovisN/AN/AN/AN/AN/AIRMDiRadimed$0.680.91%N/A41.98%1 YearsSLNOSoleno TherapeuticsN/AN/AN/AN/AN/ATMDXTransMedics GroupN/AN/AN/AN/AN/ALatest IRMD, TMDX, SLNO, and ENOV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/31/2025IRMDiRadimedquarterly$0.171.13%8/18/20258/18/20258/28/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENOVEnovis0.532.251.15IRMDiRadimedN/A8.787.51SLNOSoleno Therapeutics0.2115.1315.01TMDXTransMedics Group1.619.869.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENOVEnovis98.45%IRMDiRadimed92.34%SLNOSoleno Therapeutics97.42%TMDXTransMedics Group99.67%Insider OwnershipCompanyInsider OwnershipENOVEnovis2.70%IRMDiRadimed36.80%SLNOSoleno Therapeutics6.40%TMDXTransMedics Group7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENOVEnovis7,36757.16 million55.62 millionOptionableIRMDiRadimed11012.72 million8.04 millionOptionableSLNOSoleno Therapeutics3053.15 million49.74 millionOptionableTMDXTransMedics Group21034.09 million31.70 millionOptionableIRMD, TMDX, SLNO, and ENOV HeadlinesRecent News About These CompaniesNew York State Teachers Retirement System Buys 5,689 Shares of TransMedics Group, Inc. $TMDX4 hours ago | marketbeat.comTransMedics Group: Guidance Up, Durability In QuestionOctober 20 at 12:41 PM | seekingalpha.comTransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of "Moderate Buy" by AnalystsOctober 20 at 3:11 AM | americanbankingnews.comTransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Rating of "Moderate Buy" by AnalystsOctober 20 at 2:37 AM | marketbeat.comTransMedics Group (NASDAQ:TMDX) Rating Increased to Buy at Wall Street ZenOctober 18 at 2:50 AM | marketbeat.comTransMedics Group, Inc. $TMDX Shares Sold by Vontobel Holding Ltd.October 16, 2025 | marketbeat.comTransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025October 15, 2025 | prnewswire.comTransMedics Group (NASDAQ:TMDX) Coverage Initiated at Jefferies Financial GroupOctober 15, 2025 | americanbankingnews.comTransMedics Group Advances Healthcare Amid Nasdaq 100 Index RiseOctober 14, 2025 | kalkinemedia.comKTransMedics Group Stock Earns Relative Strength Rating UpgradeOctober 14, 2025 | msn.comTransMedics Group (NASDAQ:TMDX) Earns "Buy" Rating from Canaccord Genuity GroupOctober 14, 2025 | marketbeat.comTotal Clarity Wealth Management Inc. Invests $386,000 in TransMedics Group, Inc. $TMDXOctober 14, 2025 | marketbeat.comHere's How Much $1000 Invested In TransMedics Group 5 Years Ago Would Be Worth TodayOctober 14, 2025 | benzinga.comJefferies Initiates Coverage of TransMedics Group (TMDX) with Buy RecommendationOctober 13, 2025 | msn.com4 Analysts Have This To Say About TransMedics GroupOctober 13, 2025 | benzinga.comTransMedics Group (NASDAQ:TMDX) Earns Buy Rating from Analysts at Jefferies Financial GroupOctober 13, 2025 | marketbeat.comBlair William & Co. IL Trims Stock Holdings in TransMedics Group, Inc. $TMDXOctober 12, 2025 | marketbeat.comSLT Holdings LLC Makes New Investment in TransMedics Group, Inc. $TMDXOctober 11, 2025 | marketbeat.comTransMedics Group, Inc. $TMDX Shares Acquired by Valmark Advisers Inc.October 10, 2025 | marketbeat.comWeiss Ratings Reaffirms Hold (C) Rating for TransMedics Group (NASDAQ:TMDX)October 9, 2025 | marketbeat.comThere's Been No Shortage Of Growth Recently For TransMedics Group's (NASDAQ:TMDX) Returns On CapitalOctober 9, 2025 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIRMD, TMDX, SLNO, and ENOV Company DescriptionsEnovis NYSE:ENOV$32.41 +0.99 (+3.15%) Closing price 10/20/2025 03:59 PM EasternExtended Trading$32.76 +0.35 (+1.08%) As of 10/20/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.iRadimed NASDAQ:IRMD$74.69 +1.26 (+1.72%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$74.45 -0.24 (-0.32%) As of 07:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.Soleno Therapeutics NASDAQ:SLNO$65.45 -0.02 (-0.03%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$66.46 +1.01 (+1.54%) As of 07:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.TransMedics Group NASDAQ:TMDX$119.90 +2.27 (+1.93%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$120.28 +0.38 (+0.31%) As of 07:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall? Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
